Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 7/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16759870 | 0.91 | CASP1 (0.38) | ENPP2ATXN2CASP1HSD17B10NAMPT | |
| SCHEMBL22911090 | 0.91 | CASP1 (0.38) | ENPP2ATXN2CASP1HSD17B10NAMPT | |
| SCHEMBL22911094 | 0.91 | MGLL (0.38) | NAMPTMGLLKMT2A | |
| SCHEMBL22910584 | 0.85 | KDM4E (0.38) | ENPP2ATXN2CASP1HSD17B10PROKR1 | |
| SCHEMBL16759781 | 0.85 | KDM4E (0.38) | ENPP2ATXN2CASP1HSD17B10PROKR1 | |
| SCHEMBL22911144 | 0.84 | MGLL (0.37) | MGLLKMT2A | |
| SCHEMBL22910813 | 0.83 | PDK2 (0.36) | ENPP2ATXN2MGLL | |
| SCHEMBL22911089 | 0.83 | HCRTR1 (0.34) | MGLLKMT2A | |
| SCHEMBL22911086 | 0.82 | CNR2 (0.36) | ATXN2MGLL | |
| SCHEMBL16759787 | 0.81 | PDE3B (0.42) | NAMPTSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | ENPP2 2448/4885ATXN2 1316/4885CASP1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.